OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a report published on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.06.

OncoCyte Price Performance

NASDAQ OCX traded down $0.03 during trading on Friday, reaching $3.00. The company's stock had a trading volume of 27,219 shares, compared to its average volume of 29,446. The firm has a fifty day moving average of $3.07 and a 200 day moving average of $2.95. OncoCyte has a one year low of $2.08 and a one year high of $4.34.

OncoCyte (NASDAQ:OCX - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The company had revenue of $0.10 million during the quarter.

Insider Activity

In related news, CFO Andrea S. James acquired 33,670 shares of the stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company's stock, valued at $99,999.90. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Andrea S. James acquired 33,670 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company's stock, valued at $99,999.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares of the company's stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.58% of the company's stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.